Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

Breast Cancer Research and Treatment

Volumn 152, Issue 1, 2015, Pages 67-76

  Vulsteke, Christof ^a   Pfeil, Alena M ^b   Maggen, Charlotte ^c   Schwenkglenks, Matthias ^b   Pettengell, Ruth ^d   Szucs, Thomas D ^b   Lambrechts, Diether ^e,f   Dieudonné, Anne Sophie ^c   Hatse, Sigrid ^c   Neven, Patrick ^c   Paridaens, Robert ^c   Wildiers, Hans ^c  

^a Integrated Cancer Center Ghent AZ Maria Middelares   (Belgium)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anthracycline induced cardiotoxicity; Early breast cancer; Genetic variability; Left ventricular ejection fraction

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC ANTIBIOTIC; TUMOR MARKER;

ABCC1 GENE; ABCC2 GENE; ADULT; AGED; ANTHRACYCLINE INDUCED CARDIOTOXICITY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOTOXICITY; CYBA GENE; FEBRILE NEUTROPENIA; FEMALE; GENETIC RISK; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NCF4 GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAC2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC28A3 GENE; TUMOR GENE; ALLELE; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; HEART STROKE VOLUME; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ALLELES; ANTIBIOTICS, ANTINEOPLASTIC; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARDIOTOXICITY; EPIRUBICIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; STROKE VOLUME; YOUNG ADULT;

EID: 84931009337     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3437-9     Document Type: Article

References (36)

1. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24(36):5664–5671
2. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA (2002) frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13(6):819–829
3. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125(1):47–58
4. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8(8):1039–1058
5. Roca-Alonso L, Pellegrino L, Castellano L, Strebbin J (2012) Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 122(4):253–259
6. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, Rosenthal D (2007) Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 25(24):3635–3643
7. Wildiers H, Jurcut R, Ganame J, Herbots L, Neven P, De Backer J, Denys H, Cocquyt V, Rademakers F, Voigt JU, Paridaens R (2008) A Pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. Crit Rev Hematol 67(2):133–138
8. Jurcut R, Wildiers H, Ganame J, D’hooge J, De Backer J, Denys H, Paridaens R, Rademakers F, Voigt JU (2008) Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 21(12):1283–1289
9. Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24:1513–1525
10. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT (2012) ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblatic leukaemia. Cell Biol Int 36(1):79–86
11. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmöller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24):3754–3762
12. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, AL-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30(13):1422–1428
13. Visscher H, Ross CJ, Rassekh SR, Sandro GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, CPNDS Consortium (2013) Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 60(8):1375–1381
14. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J (2009) Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to leukemia in childhood. Leuk Lymphoma 50(10):1693–1698
15. Cascales A, Pastor-Quirante F, Sanchez-Vega B, Luengo-Gil G, Corral J, Ortuno-Pacheco G, Vicente V, de la Pena FA (2013) Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist. 18(4):446–453
16. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J Clin Oncol 30(13):1415–1421
17. Lubieniecka J, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti T, Riggs W (2013) A discovery study of daunorubicine induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front Genet 11(4):231
18. Onitilo AA, Engel JM, Stankowski RV et al (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 5(4):154–166
19. Goldhirsch A, Winer E, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223
20. U.S. Department of Health and Human services, national institutes of health, national cancer institute. Cancer therapy Evaluation program-Common terminology Criteria for Adverse Events (CTCAE)-version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010)
21. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete resmission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685
22. Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H (2014) Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Res Treat 147(3):557–570
23. Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H (2014) Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer 19(14):201
24. Reumers J, De Rijk P, Zhao H et al (2011) Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol 30:61–68
25. Sun L, Craiu RV, Paterson AD, Bull SB (2006) Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. Genetic Epidemiol 30(6):519–530
26. Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Source Code Biol Med 16(3):17
27. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302
28. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131
29. Frei BL, Soefje SAE (2008) A review of the cardiovascular effects of oncology agents. J Pharm Pract 21:146–158
30. Shah C, Badiyan S, Berry S, Khan AJ, Goyal S, Schulte K, Nanavati A, Lynch M, Vicini FA (2014) Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiotherapy Oncol. 112(1):9–16
31. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166
32. Cole SP, Bhardwaj G, Gerlach JH et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654
33. Flens MJ, Gj Zaman, van der Valk P et al (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237–1247
34. Wang X, Liu W, Sun CL, Armenian SH, Hakonarson H, Hageman L, Ding Y, Landier W, Blanco JG, Chen L, Quinones A, Ferguson D, Winick N, Ginsberg JP, Keller F, Neglia JP, Desai S, Sklar CA, Castellino SM, Cherrick I, Dreyer ZE, Hudson MM, Robison LL, Yasui Y, Relling MV, Bhatia S (2014) Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol 32(7):647–653
35. Bristow MR, Billingham ME, Mason JW, Daniels JR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873–879
36. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815